Trial Profile
Phase 1 safety study of LUM002 in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2014
Price :
$35
*
At a glance
- Drugs Volixibat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Lumena Pharmaceuticals; Sanofi
- 26 Jun 2014 New trial record